Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Insight Molecular Diagnostics' Change in Accured Expenses rose 8135.59% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$205000.0, marking a year-over-year increase of 3189.37%. This contributed to the annual value of $967000.0 for FY2024, which is 12032.79% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Change in Accured Expenses stood at $1.2 million, which was up 8135.59% from -$3.1 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Change in Accured Expenses peaked at $1.2 million during Q3 2025, and registered a low of -$3.1 million during Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' median Change in Accured Expenses value was $126000.0 (recorded in 2023), while the average stood at -$302631.6.
  • In the last 5 years, Insight Molecular Diagnostics' Change in Accured Expenses tumbled by 1257619.05% in 2023 and then soared by 41507.94% in 2024.
  • Insight Molecular Diagnostics' Change in Accured Expenses (Quarter) stood at $244000.0 in 2021, then plummeted by 151.23% to -$125000.0 in 2022, then plummeted by 351.2% to -$564000.0 in 2023, then soared by 224.82% to $704000.0 in 2024, then skyrocketed by 67.19% to $1.2 million in 2025.
  • Its Change in Accured Expenses stands at $1.2 million for Q3 2025, versus -$3.1 million for Q2 2025 and $1.0 million for Q1 2025.